GlassScriptPhysician profile
Douglas Christopher Walsh
NPI 1750356929
$4,171.08
in general payments reported to CMS, 2019-2025
37 companies · $721 in 2025
The $721 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $374 · 2021: $463 · 2022: $717 · 2023: $860 · 2024: $459 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,039.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,271.74 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $467.59 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $435.62 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $389.49 | 2019-2025 | Xifaxan |
| Celgene Corporation | $275.54 | 2021-2024 | Zeposia |
| Pfizer INC. | $189.45 | 2019-2025 | |
| Ardelyx, INC. | $152.59 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $96.89 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $84.81 | 2019-2023 | Ocaliva |
| Covidien LP | $77.00 | 2019 | |
| Mirum Pharmaceuticals, INC. | $71.52 | 2025 | Livmarli |
| Gilead Sciences, INC. | $59.16 | 2025 | |
| Braintree Laboratories, INC. | $56.29 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $50.78 | 2022-2023 | Terlivaz |
| Cumberland Pharmaceuticals, INC. | $46.21 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $45.31 | 2023-2025 | Sucraid |
| Amgen INC. | $37.26 | 2023 | Avsola, Amjevita |
| Genzyme Corporation | $37.02 | 2024 | |
| Ferring Pharmaceuticals INC. | $28.22 | 2019-2020 | |
| Allergan, INC. | $27.21 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.65 | 2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $22.63 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $21.28 | 2025 | Vegzelma |
| Olympus America INC. | $19.83 | 2019 | |
| Echosens North America, INC. | $19.82 | 2023 | Fibroscan |
| Aimmune Therapeutics, INC. | $18.97 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $18.69 | 2021 | |
| Daiichi Sankyo INC. | $17.76 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.08 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $15.40 | 2022 | |
| Siemens Medical Solutions USA, INC. | $14.75 | 2019 | |
| Redhill Biopharma INC. | $13.50 | 2022 | |
| Boston Scientific Corporation | $12.42 | 2022 | |
| Merck Sharp & Dohme LLC | $12.05 | 2022 | |
| Romark Laboratories, Lc | $11.42 | 2020 | |
| Ucb, INC. | $11.13 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$62,577.28 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.